Plus Therapeutics
PSTV
7 hedge funds and large institutions have $117K invested in Plus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1% less capital invested
Capital invested by funds: $118K → $117K (-$1K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$26.3K |
| 2 |
VF
Virtu Financial
New York
|
+$13.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$6.58K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $54K | -$6.58K | -1 | -9% |
|
|
2
Barclays
London,
United Kingdom
| $29K | +$26.3K | +4 | +400% |
|
|
VF
3
Virtu Financial
New York
| $12K | +$13.2K | +2 | New |
|
4
BlackRock
New York
| $7K | – | – | – |
|
|
PCM
5
Perkins Capital Management
Wayzata,
Minnesota
| $5K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $4K | – | – | – |
|
|
MOS
7
MGO One Seven
Beachwood,
Ohio
| $3K | – | – | – |
|
8
Macquarie Group
Sydney, NSW 2000,
Australia
| $2K | – | – | – |
|
|
LTFS
9
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
|
FDCDDQ
10
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $4 | – | – | – |
|
PSTV Hedge Fund Activity: Q4 2018 in Review
7 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2018, worth a combined $117K — down 0.85% from $118K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PSTV positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Barclays, adding an estimated $26.3K. The largest seller was Renaissance Technologies, cutting an estimated $6.58K.
- 7 institutional investors held Plus Therapeutics (PSTV) as of Q4 2018, up from 6 in Q3 2018.
- Funds reported $117K of Plus Therapeutics stock for Q4 2018, down 0.85% quarter-over-quarter.
- 1 fund opened new Plus Therapeutics positions in Q4 2018 and 0 closed out, a net change of +1 holder.
- The largest Plus Therapeutics buyer in Q4 2018 was Barclays, an estimated $26.3K added.
- The largest Plus Therapeutics seller in Q4 2018 was Renaissance Technologies, an estimated $6.58K sold.
Based on aggregated 13F filings for Q4 2018.